9781604272147 - decision analysis and portfolio management in the biopharma industry: a practitioner’s guide di bayney, richard; orellana, jose (8 risultati)
- Rilegato
Da: Rarewaves USA, OSWEGO, IL, U.S.A.Rarewaves USA
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 112,29
Spedizione gratuitaSpedito in U.S.A.Quantità: Più di 20 disponibili
Hardback. Condizione: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainabilit…y. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.
- Rilegato
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.Grand Eagle Retail
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 112,30
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: new. Hardcover. Biopharmaceutical R&D stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sus…tainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of R&D organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
- Rilegato
Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 136,15
EUR 14,59 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: Brand New. 340 pages. 7.00x0.90x10.00 inches. In Stock.
- Rilegato
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 104,37
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Condizione: New.
- Rilegato
Da: Rarewaves USA United, OSWEGO, IL, U.S.A.Rarewaves USA United
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 136,47
EUR 43,45 spedizioneSpedito in U.S.A.Quantità: Più di 20 disponibili
Hardback. Condizione: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainabilit…y. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.
- Rilegato
Da: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 201,88
EUR 9,12 spedizioneSpedito in U.S.A.Quantità: 10 disponibili
Condizione: New. 2026. hardcover. . . . . . Books ship from the US and Ireland.
- Rilegato
Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 231,74
EUR 9,50 spedizioneSpedito da Irlanda a U.S.A.Quantità: 10 disponibili
Condizione: New. 2026. hardcover. . . . . .
- Rilegato
Da: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 216,66
EUR 32,15 spedizioneSpedito da Australia a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: new. Hardcover. Biopharmaceutical R&D stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sus…tainability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of R&D organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
